More personalised medicine for lung cancer: benefits and barriers
EDITED: 18/07/2018 | PUBLISHED: 13/01/2017
The All-Party Parliamentary Group on Personalised Medicine held a roundtable discussion in the House of Lords on Tuesday 28 February. Parliamentarians and experts from across the medical, academic, corporate and public sectors came together to explore patient needs and scientific opportunities for more personalised and effective care for people with lung cancer.
Attendees were welcomed by APPG Chair Jo Churchill MP before hearing Janette Rawlinson, a lung cancer survivor and active participant in her local Clinical Commissioning Group, offer important insights from a patient perspective on what matters to patients.
Presenting views from clinicians were Dr Sanjay Popat (Consultant Thoracic Medical Oncologist, The Royal Marsden) and Dr Robert Rintoul (Consultant Respiratory Physician, Papworth Hospital), who discussed the benefits of more personalised care for lung cancer, focusing respectively on circulating tumour DNA testing and breath biopsy for earlier diagnosis.
The meeting concluded with a lively Q&A where attendees posed questions on how the most effective innovations could be translated from research into routine NHS care, ways to raise clinician awareness of developments in practice especially in general practice, and the need to incorporate patients into their care plan.
At the next meeting the APPG will consider personalised medicine for cardiovascular disease.